Pierre Massion
Faculty Member
Last active: 1/11/2018

  1. Early detection of NSCLC with scFv selected against IgM autoantibody. Pedchenko T, Mernaugh R, Parekh D, Li M, Massion PP (2013) PLoS One 8(4): e60934
    › Primary publication · 23585862 (PubMed) · PMC3621672 (PubMed Central)
  2. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V (2013) BMC Syst Biol : S1
    › Primary publication · 24564859 (PubMed) · PMC4029366 (PubMed Central)
  3. Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. Pass HI, Beer DG, Joseph S, Massion P (2013) Thorac Surg Clin 23(2): 211-24
    › Primary publication · 23566973 (PubMed)
  4. ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. Giacalone NJ, Den RB, Eisenberg R, Chen H, Olson SJ, Massion PP, Carbone DP, Lu B (2013) Future Oncol 9(5): 737-45
    › Primary publication · 23647301 (PubMed) · PMC5341386 (PubMed Central)
  5. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, Gingras O, Lamontagne J, Allard R, Chelsky D, Price ND, Lam S, Massion PP, Pass H, Rom WN, Vachani A, Fang KC, Hood L, Kearney P (2013) Sci Transl Med 5(207): 207ra142
    › Primary publication · 24132637 (PubMed) · PMC4114963 (PubMed Central)
  6. The state of molecular biomarkers for the early detection of lung cancer. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP (2012) Cancer Prev Res (Phila) 5(8): 992-1006
    › Primary publication · 22689914 (PubMed) · PMC3723112 (PubMed Central)
  7. Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Nagathihalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK (2012) Mol Cancer Ther 11(11): 2362-72
    › Primary publication · 22933707 (PubMed) · PMC3969334 (PubMed Central)
  8. ROS1 rearrangements define a unique molecular class of lung cancers. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (2012) J Clin Oncol 30(8): 863-70
    › Primary publication · 22215748 (PubMed) · PMC3295572 (PubMed Central)
  9. Poor survival for veterans with pathologic stage I non-small-cell lung cancer. St Julien JB, Pinkerman R, Aldrich MC, Chen H, Deppen SA, Callaway-Lane C, Massion P, Putnam JB, Lambright ES, Nesbitt JC, Grogan EL (2012) Am J Surg 204(5): 637-42
    › Primary publication · 22906246 (PubMed) · PMC3766956 (PubMed Central)
  10. Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation. Massion PB, Peters P, Ledoux D, Zimermann V, Canivet JL, Massion PP, Damas P, Gothot A (2012) Intensive Care Med 38(8): 1326-35
    › Primary publication · 22735856 (PubMed)